Akura Medical
- Industry
- Medical Devices & Equipment
- Founded Year
- 2019
- Headquarters
- 170 Knowles Drive, Los Gatos, California, 95032, United States
- Employee Count
- 30
Key People
- Murali Srivathsa - President and CEO
- Amr Salahieh - Co-Founder and Chairman
- Aadel Al-Jadda - Co-Founder and VP of R&D
- David Voris - Chief Financial Officer
- Eric Lang - VP of Operations
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises seasoned MedTech professionals with a track record of successful ventures.
The presence of multiple successful MedTech entrepreneurs in the leadership team enhances the company's credibility and potential for success.
- Clinical Need
-
Aspect: Very Strong
Summary: Venous thromboembolism (VTE) is a significant health concern with high mortality rates, indicating a strong clinical need for effective treatments.
VTE affects a large patient population, and current treatments have limitations, underscoring the need for innovative solutions.
- Competition
-
Aspect: Very crowded + Strategics
Summary: The thrombectomy device market is highly competitive, with numerous established players.
The presence of multiple competitors, including large strategic companies, makes it challenging for new entrants to gain market share.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing a next-generation thrombectomy device involves moderate technical challenges.
While the technology is feasible, achieving differentiation and efficacy requires careful design and testing.
- Patent
-
Aspect: Applied
Summary: The company has applied for patents to protect its technology.
Securing patents can provide a competitive edge and protect the company's innovations from imitation.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding, including a $35M Series B round.
Substantial funding enables the company to advance its technology, conduct clinical trials, and scale manufacturing.
- Regulatory
-
Aspect: Running FIH
Summary: The company is conducting first-in-human trials as part of its regulatory pathway.
Successfully completing first-in-human trials is a critical step toward regulatory approval and market entry.
Opportunity Rollup
- Odds of Success
- 3.7
- Peak Market Share
- 4.3
- Segment CAGR
- 9.4%
- Market Segment
- Clot Management Devices
- Market Sub Segment
- Mechanical Thrombectomy Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.22 |
| 2 | 0.64 |
| 3 | 1.50 |
| 4 | 3.01 |
| 5 | 4.30 |
Key Takeaway
Akura Medical, with its experienced team and innovative thrombectomy platform, is well-positioned to address the significant clinical need in VTE treatment, despite facing a competitive market landscape.